Literature DB >> 28849347

The impact of comorbidities on hip fracture mortality: a retrospective population-based cohort study.

Mikk Jürisson1, Mait Raag2, Riina Kallikorm3,4, Margus Lember3,4, Anneli Uusküla2.   

Abstract

The impact of comorbidities on hip fracture-related excess mortality was assessed in a population-based age- and sex-matched cohort over 10 years. On average, only 1 out of 12 excess deaths over 10 years was related to pre-fracture life-threatening comorbidities. The presence of life-threatening comorbidities increased the excess risk of death after hip fracture.
PURPOSE: This work aimed to estimate the impact of pre-fracture comorbidities on the 10-year excess risk of all-cause death after hip fracture among Estonian men and women ≥ 50 years of age.
METHODS: Retrospective, population-based 10-year study of people aged ≥ 50 in two cohorts: those with a hip fracture and an age- and sex-matched random sample from the national health insurance fund for comparison.
RESULTS: We found that hip fracture was a strong independent risk factor for death. Upon adjustment for Charlson Comorbidities Index (CCI) score, the impact of life-threatening comorbidities on average hip fracture-related excess mortality was modest: only 8% of excess deaths over 10 years were related to comorbidities. Upon stratification by CCI groups, the excess risk of patients in CCI groups ≥ 3 and 1-2 exceeded that in the CCI 0 group over 5-7 years, indicating that in patients with life-threatening comorbidities, a hip fracture accelerates the chain of lethal events and brings deaths from other conditions forward. The impact of comorbidities was age- and time-dependent: in younger hip fracture patients, the comorbidities almost doubled the excess risk from a fracture in 10 years; in older patients, the effect was shorter and modest.
CONCLUSIONS: The presence of pre-fracture comorbidities increases the risk of excess death in hip fracture patients, but the comorbidity impact on aggregated excess mortality is modest.

Entities:  

Keywords:  Charlson comorbidity index; Comorbidities; Hip fracture; Mortality

Mesh:

Year:  2017        PMID: 28849347     DOI: 10.1007/s11657-017-0370-z

Source DB:  PubMed          Journal:  Arch Osteoporos            Impact factor:   2.617


  6 in total

1.  Comorbidity and mortality after hip fracture in nineteen thousand six hundred and eighty two patients aged eighteen to sixty five years in Denmark from 1996 to 2012.

Authors:  Adam Omari; Christian Medom Madsen; Jes Bruun Lauritzen; Henrik Løvendahl Jørgensen; Fie Juhl Vojdeman
Journal:  Int Orthop       Date:  2019-03-23       Impact factor: 3.075

2.  Risk factors of mortality and second fracture after elderly hip fracture surgery in Shanghai, China.

Authors:  Minmin Chen; Yanping Du; Wenjing Tang; Weijia Yu; Huilin Li; Songbai Zheng; Qun Cheng
Journal:  J Bone Miner Metab       Date:  2022-08-08       Impact factor: 2.976

3.  Determinants of Higher Mortality at Six Months in Patients with Hip Fracture: A Retrospective Study.

Authors:  Enrique González-Marcos; Enrique González-García; Paula Rodríguez-Fernández; Esteban Sánchez-González; Jerónimo J González-Bernal; Josefa González-Santos
Journal:  J Clin Med       Date:  2022-04-29       Impact factor: 4.964

4.  Simple Excel and ICD-10 based dataset calculator for the Charlson and Elixhauser comorbidity indices.

Authors:  Pärt Prommik; Kaspar Tootsi; Helgi Kolk; Aare Märtson; Toomas Saluse; Eiki Strauss
Journal:  BMC Med Res Methodol       Date:  2022-01-07       Impact factor: 4.615

5.  The role of routine postoperative laboratory tests following hip hemiarthroplasty for an elderly femoral neck fracture.

Authors:  Teng-Feng Zhuang; Song-Wei Huan; Si-Min Luo; Guo-Rong She; Wen-Rui Wu; Jun-Yuan Chen; Ning Liu; Zhen-Gang Zha
Journal:  BMC Musculoskelet Disord       Date:  2021-09-18       Impact factor: 2.362

6.  The effect of the comorbidity burden on vitamin D levels in geriatric hip fracture.

Authors:  Ing How Moo; Carmen Jia Wen Kam; Eric Wei Liang Cher; Bryan Ce Jie Peh; Chung Ean Lo; David Thai Chong Chua; Ngai Nung Lo; Tet Sen Howe; Joyce Suang Bee Koh
Journal:  BMC Musculoskelet Disord       Date:  2020-08-08       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.